L-DOPA treatment from the viewpoint of neuroprotectionPossible mechanism of specific and progressive dopaminergic neuronal death in Parkinson’s disease

被引:0
|
作者
Norio Ogawa
Masato Asanuma
Ikuko Miyazaki
Francisco J. Diaz-Corrales
Ko Miyoshi
机构
[1] Okayama University Graduate School of Medicine & Dentistry,Dept. of Brain Science
来源
Journal of Neurology | 2005年 / 252卷
关键词
dopamine quinone; oxidative stress; mitochondrial dysfunction; inflammation; -DOPA; remodelling; rotenone;
D O I
暂无
中图分类号
学科分类号
摘要
With regard to the mechanism of selective dopaminergic neuronal death, experimental results of studies on the neurotoxicity of MPTP and rotenone indicate that degeneration of dopamine neurons is closely related to mitochondrial dysfunction, inflammatory process and oxidative stress, particularly with regard to the generation of quinones as dopamine neuron-specific oxidative stress. Thus, it is now clear that the presence of high levels of discompart-mentalized free dopamine in dopaminergic neurons may explain the specific vulnerability of dopaminergic neurons through the generation of highly toxic quinones.
引用
收藏
页码:iv23 / iv31
相关论文
共 50 条
  • [31] Paradoxical response to L-dopa and apomorphine in the Parkinson's disease
    García-Soldevilla, MA
    Puertas, I
    Barcenilla, B
    Sayed, Y
    García-Albea, E
    Jiménez-Jiménez, FJ
    MOVEMENT DISORDERS, 2002, 17 : S96 - S96
  • [32] Parkinson's disease, L-DOPA, and endogenous morphine: A revisit
    Stefano, George B.
    Mantione, Kirk J.
    Kralickova, Milena
    Ptacek, Radek
    Kuzelova, Hana
    Esch, Tobias
    Kream, Richard M.
    MEDICAL SCIENCE MONITOR, 2012, 18 (08): : RA133 - RA137
  • [33] L-DOPA for Parkinson's disease-a bittersweet pill
    Lane, Emma L.
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2019, 49 (03) : 384 - 398
  • [34] L-DOPA: A scapegoat for accelerated neurodegeneration in Parkinson's disease?
    Lipski, Janusz
    Nistico, Robert
    Berretta, Nicola
    Guatteo, Ezia
    Bernardi, Giorgio
    Mercuri, Nicola B.
    PROGRESS IN NEUROBIOLOGY, 2011, 94 (04) : 389 - 407
  • [35] Parkinson's disease: Progression and mortality in the L-DOPA era
    DiRocco, A
    Molinari, SP
    Kollmeier, B
    Yahr, MD
    PARKINSON'S DISEASE, 1996, 69 : 3 - 11
  • [36] L-dopa impairs associative learning in Parkinson's disease
    Shohamy, D
    Myers, CE
    Onlaor, S
    Gluck, MA
    JOURNAL OF COGNITIVE NEUROSCIENCE, 2002, : 84 - 84
  • [37] Beyond L-DOPA: hope for Parkinson's treatment and diagnosis
    不详
    EBIOMEDICINE, 2017, 23 : 1 - 1
  • [38] Dynamics of Cognitive Impairments in Patients with Parkinson’s Disease Receiving L-DOPA Treatment
    Ismailova S.B.
    Prokopenko S.V.
    Pokhabov D.V.
    Mosaleva E.I.
    Alekseenko P.V.
    Zhumzhanov I.M.
    Neuroscience and Behavioral Physiology, 2022, 52 (3) : 368 - 372
  • [39] Elevated Homocysteine Levels in Parkinson's Disease: Is there Anything Besides L-Dopa Treatment?
    Zoccolella, S.
    dell'Aquila, C.
    Specchio, L. M.
    Logroscino, G.
    Lamberti, P.
    CURRENT MEDICINAL CHEMISTRY, 2010, 17 (03) : 213 - 221
  • [40] Hallmarks of Treatment Aspects: Parkinson's Disease Throughout Centuries Including L-Dopa
    Kim, Hee J.
    Jeon, Beom S.
    Jenner, Peter
    PARKINSON'S DISEASE, 2017, 132 : 295 - 343